Immuno-Oncology Drug Development: Challenges & Next Steps

PharmaTalk Radio's Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD, National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what's currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they also address:

• Ipilumumab/Nivo/Pembro challenges
• What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
• Challenges with the following modalities: Checkpoints, Oncolytic Virus', Adoptive T-Cells, Cancer Vaccines
• Blinitumumab
• The more interesting agents in late stage development now in immunotherapy and its promise
• Immune related adverse events
• Adoptive cellular therapies, what is the most promising?
• Will IO become backbone therapies for cancer?
• What's the next set of assets that are going to come out?
• Promises in combination therapies?
• What can we expect next?

Guests:

James Gulley, MD, PhD
Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline

The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016  at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.